Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group
Makaleler > Tam Makale · 2026
Yazarlar: Burcu ÇAKAR, Sercan ÖN, Selin Cebeci, Zeynep Hande Turna, Zeynep Gülsüm Güç Sevgen, Deniz can güven, Sadettin Kılıçkap, Mehmet Nuri Başer, Bilgin Demir, Sedat Biter, Ertuğrul Bayram, Berkay Yeşilyurt, Doğan Uncu, Ahmet Melih Arslan, Elif Atağ Akyürek, Hayati Arvas, Zuhat Urakçı, Teoman Şakalar, Ferit aslan, Mehmet Uzun, Mustafa Yıldırım, Ahmet Unlu, Derya kıvrak salim, Atike Pınar Erdoğan, Elif Şahin, Şeyda Gündüz, Burcu Gülbağcı, Şaziye Burçak Karaca Yayla
CANCERS, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Emerging Sources Citation Index (ESCI), 2026, cilt 18, ss 394-408
DOI: 2072-6694/18/3/394
Özet
<p><strong style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">Background/Objectives</strong><span style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">: Uveal melanoma (UM) is a subtype of melanoma that originates from the uveal layer of the eye (iris, ciliary body, choroid) and is biologically distinct from cutaneous melanoma. The real-world evidence on treatment patterns and survival outcomes, particularly from non-Western populations, remains limited. This study provides a comprehensive national overview of local and systemic management of UM across Türkiye. </span><strong style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">Methods</strong><span style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">: This multicenter retrospective cohort study, coordinated by the Turkish Oncology Group (TOG), included patients diagnosed with UM between 2012 and 2025 across 19 tertiary oncology centers. Clinical characteristics, treatment patterns, and outcomes were analyzed. Systemic therapies were subgrouped as immunotherapy or cytotoxic chemotherapy. Progression-free survival (PFS) and overall survival (OS) were assessed by the Kaplan–Meier method; prognostic factors for OS were analyzed by Cox regression. </span><strong style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">Results</strong><span style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">: A total of 113 patients were included; 89.4% presented with localized disease. During follow-up, 43.4% developed metastases, predominantly hepatic (93.5%). 47.4% of metastatic patients received liver-directed treatments; the most common treatment was radioembolization, and these treatments were associated with longer OS. Among 59 patients receiving systemic therapy, immunotherapy demonstrated higher ORR and DCR than chemotherapy across treatment lines, although small subgroup sizes limited statistical significance. Dual immune checkpoint blockade emerged as an independent favorable prognostic factor in multivariate analysis. Median OS for metastatic patients was 16 months (95% CI: 9.3–22.7). HLA-A*02:01 was positive in 29.4% of patients tested, and only three patients received tebentafusp. </span><strong style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">Conclusions</strong><span style="background-color: rgb(255, 255, 255); color: rgb(11, 12, 14);">: This large national cohort highlights substantial real-world heterogeneity in treatment patterns and confirms the limited efficacy of chemotherapy, the prognostic benefit of dual ICI therapy, and the potential survival advantage of liver-directed treatments in selected patients. Low HLA-A*02:01 positivity and limited access to tebentafusp remain major challenges in Türkiye. These findings provide an essential benchmark for improving treatment strategies in metastatic UM.</span></p>